Displaying 1–14 of 14 results for Girish Malhotra, President, EPCOT International
FINAL DOSE: How to spur technological advancements in pharma.
Pharmaceutical Manufacturing is honored to welcome three new editorial advisory board members, as we continue our ongoing quest to keep our brand current and unique.
CPhI Worldwide's 2017 Pharma Predictions: The Good, the Bad, and the Donald. Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities.
Selection of any pharma manufacturing process, including supply chain and quality assurance practices, requires financial justification
Pharmaceutical manufacturing capacity is increasingly global and going biologic, but challenged to meet the realities of cGMP
Never a dull moment these days at Ranbaxy Laboratories, Indias largest drug manufacturer. In the course of the summer, it has resolved its longstanding, much-publicized patent dispute with Pfizer over its generic version of Lipitor, agreed to an imminent buyout by Japanese drugmaker Daiichi ...
PAT and QbD can only move forward if the industry sheds its habit of QbA (i.e., quality by analysis)
API process development expert Girish Malhotra explores this question and its relevance to both Indian innovation and global competition in pharmaceuticals.
Generic drug manufacturers must grapple with the tightest of all pharmaceutical profit margins. This is especially true of generic manufacturers in developing countries. Branded drug makers had not suffered from such constraints in the past, but this situation is about to change.
API manufacturers in India and China have grasped the need for simplicity, while U.S. process chemists continue along their costly and complex path. Girish Malhotra shares recommendations for improved API process development.